Group items matching

in title, tags, annotations or url

This Funding Opportunity Announcement (FOA) invites grant applications for the Outstanding Investigator Award (R35) in any area of cancer research. The objective of the National Cancer Institute (NCI) Outstanding Investigator Award (OIA) is to provide long-term support to accomplished investigators with outstanding records of cancer research productivity who propose to conduct exceptional research. The OIA is intended to allow investigators the opportunity to take greater risks, be more adventurous in their lines of inquiry, or take the time to develop new techniques. The OIA would allow an Institution to submit applications nominating established Program Directors/Principal Investigators (PDs/PIs) for the NCI OIA. It is expected that the OIA would provide extended funding stability and encourage investigators to embark on projects of unusual potential in cancer research. The research projects should break new ground or extend previous discoveries toward new directions or applications that may lead to a breakthrough that will advance biomedical, behavioral, or clinical cancer research.

This Funding Opportunity Announcement (FOA) invites applications for Silvio O. Conte Digestive Diseases Research Core Centers (DDRCCs). The DDRCCs are part of an integrated program of digestive and liver diseases research support provided by the NIDDK. The purpose of this Centers program is to bring together basic and clinical investigators as a means to enhance communication, collaboration, and effectiveness of ongoing research related to digestive and/or liver diseases. DDRCCs are based on the core concept, whereby shared resources aimed at fostering productivity, synergy, and new research ideas among the funded investigators are supported in a cost-effective manner. Each proposed DDRCC must be organized around a central theme that reflects the focus of the digestive or liver diseases research of the Center members. The central theme must be within the primary mission of NIDDK, and not thematic areas for which other NIH Institutes or Centers are considered the primary source of NIH funding.

The objective of the NIDCR Award for Sustaining Outstanding Achievement in Research (SOAR) is to provide longer-term support to NIDCR-funded investigators, who are in their mid-career stage, and have outstanding records of research productivity, mentorship and professional service to the research community. It is expected that the SOAR Award will propel the investigator along this career trajectory and allow him/her to embark on ambitious longer-term projects of extraordinary potential within the mission of NIDCR. This award supports research projects for up to eight years.

The Innovation Award is for $75,000 per year, for up to two years. The award is intended to support highly promising investigators with stellar track records of accomplishment, who have the potential to advance the field of lung disease science. Successful applicants are investigators with evidence of prior excellence and productivity in the early stages of their careers; applicants must have held a K or R type award within three years prior to applying for this Lung Association award.

The overall goal of The Step Up for SUD initiative is to advance fundamental discoveries into medicines to treat substance use disorders (SUD) for the benefit of society. The purpose of this funding opportunity is to enhance and accelerate research on drug targets for SUD aiming to expand the range of targets and mechanisms in development for SUD therapies. The initiative will provide both funding and the in-kind access to biomedical product development experts.  It will be administered as a unique, short-term and nimble funding opportunity to support the confirmatory research in robust drug target validation/invalidation to allow for early decision to either proceed to a next step or stop the projects. At this point, only research projects on potential drug/biologic therapeutics, not diagnostics or devices, will be supported.

The NEI Center Core Grant combines three or more Resource and/or Service Cores for a group of R01 investigators to enhance their research, consolidate resources, avoid duplication of efforts, and/or contribute to cost effectiveness by providing a service with lower costs or higher quality than could be attempted for independent projects by several individual Program Directors/Principal Investigators (PD(s)/PI(s)). Shared resources and facilities that are accessible to a group of independently funded investigators lead to greater productivity for the separate projects and can provide instrumentation and facilities that are too costly to be maintained by an individual investigator. The design and purpose of each Center Core may vary in how it serves its users. This program is designed to enhance an institution's environment and capability to conduct vision research and to facilitate collaborative studies of the visual system and its disorders.

The Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Office of New Drugs (OND), Division of Cardiovascular and Renal Products (DCRP) is announcing its intent to accept and consider applications for the award of a grant to support the Heart Failure Collaboratory

This NOFO has two components, A and B. Component A (Natural Experiment Research Centers): To support a 5-year multi-center network of independent research centers to evaluate innovative, health system and non-health system-based natural experimental approaches to alter the diabetogenic characteristics of US communities. Applicants will select one of the following two tracks: Track 1 Evaluation of population-level programs or policies that affect population-level risk factors for type 2 diabetes (such as diet or physical activity, as well as other health behaviors; glucose; prediabetes), or Track 2 Evaluation of programs or policies aimed at improving care and management of diabetes, and the risk for diabetes complications. Component B (Coordinating Center): To fund a Coordinating Center (CC) to provide organizational, logistic and communication support to enhance the efficiency, productivity, and public health impact of the Natural Experiments research centers that are funded as part of Component A.

The purpose of this Funding Opportunity Announcement is to solicit the research applications for commercializable, digital health-based products that aim at positively affecting the fundamental social and environmental conditions that are risk factors for the populations affected by the use of drugs, including opioids.

Our goal is to connect businesses and organizations that are best-positioned to address critical needs during this public health crisis, often in innovative or unexpected ways. Then we support those businesses to do what they do best: scale products and services that can help the American public. In the immediate term, we are keenly focused on working with companies-large and small-to spur development of personal protective equipment for medical and non-medical use, novel testing solutions, widely-accessible therapeutics and health services to address the needs of underserved communities. As the crisis evolves, we will continue to be responsive by tackling other urgent priorities.

How we measure progress reveals our values and shapes our future. So what does America's portrait of progress tell us about our collective values and goals? The traditional portrait presented by most of our media and political leaders includes the Gross Domestic Product (GDP) and stock market. But do such measures really reflect our most cherished values and aspirations

The reproducibility and comparability of dietary supplement research is enhanced through rigorous analytical characterization of key experimental materials. The publication of analytical methods which have been thoroughly validated for specific, precise, accurate, and sensitive quantitative determination of chemical constituents of dietary supplements therefore makes critical contributions to the rigor and reproducibility of biomedical research. This FOA will build on existing NIH awards to support the performance and publication of formal single-laboratory validation studies of relevant quantitative analytical methods. The methods proposed for validation must be used to identify and quantify chemical constituents (active or marker chemical compounds, adulterants, contaminants) or metabolites thereof in experimental reagents, raw materials, and/or clinical specimens (for example urine or plasma samples). Methods must have been developed or utilized in fulfillment of the active parent grants specific aims. Candidate constituents for quantitative method validation studies may include (but are not limited to): phytochemicals, nutrients, and potentially deleterious substances such as pesticides and mycotoxins. Multi-laboratory validation studies will not be supported through this FOA.

The year-long Health and Aging Policy Fellows program offers fellows the opportunity to participate in a residential track or a non-residential track. The residential track allows fellows to participate in the policymaking process on either the Federal or state level as legislative assistants in Congress, professional staff members in executive branch agencies or policy organizations. The non-residential track allows fellows to remain at their home institution but work on a policy project that involves brief placement(s) throughout the year at relevant sites. Core program components focused on career development and professional enrichment are provided for fellows in both tracks. Fellows also have the opportunity to apply for second-year funding to continue components of their fellowship experience/project either at their placement sites, at the state/local levels, or with non-governmental organizations. Our key partner in this effort is the American Political Science Association which has established the most respected and longest running policy fellowship program in Washington, DC.